This excerpt taken from the CVS 10-K filed Feb 27, 2007.
Failure to complete the merger could negatively impact the stock prices and our future business and financial results.
If the merger is not completed, our ongoing businesses may be adversely affected and we will be subject to several risks, including the following:
· having to pay certain costs relating to the merger;
· the attention of our management will have been diverted to the merger instead of on our operations and pursuit of other opportunities that could have been beneficial to us;
· customer perception may be negatively impacted which could affect Pharmacares ability to compete for, or to win, new and renewal business in the marketplace; and
· being required, under certain circumstances under the merger agreement, to pay a termination fee of $675 million to Caremark.